Clinical trials: Cannabis Use Disorder, active
Alcohol Use, Cannabis Use
MATAspire: Mental Health Awareness Tailored App for Substance Prevention and Integrated Resilience Education
The MATAspire intervention is a web-app designed to promote substance misuse prevention education and bolster protective coping skills whereby students complete six weekly interactive modules using a smart device or computer.
- Conditions
- Alcohol Use, Cannabis Use, Nicotine Use, Illicit Drug Use
- Trial name
- MATAspire (NCT06553196)
- Testing
- MATAspire Web-app
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- California State University, Northridge
Cannabis Use, Substance Use Disorder (SUD)
Research Investigating Drug Effects-2 (RiDE-2)
The purpose of this study is to better understand how people's mood, behavior, and brains respond to different recreational drugs.
- Conditions
- Cannabis Use, Substance Use Disorder (SUD), Healthy
- Trial name
- RiDE-2 (NCT06758596)
- Testing
- THC
- Where
- United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- University of Illinois at Chicago
Cannabis Use, Cannabis Intoxication
Study of an Oral Fluid Testing Approach
The purpose of this study is to identify and evaluate oral fluid testing as a biologic measure of cannabis use days that can be assessed remotely.
- Conditions
- Cannabis Use, Cannabis Intoxication, Cannabis Use Disorder
- Trial name
- SOFTA (NCT06891235)
- Testing
- Biologic testing for THC
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Boston Children's Hospital
Cannabis Use Disorder
Evaluation of a Brief Computerized and Smart Phone-based Intervention for Stress in Regular Cannabis Users
The prevalence of daily cannabis use and Cannabis Use Disorder (CUD) has increased in the United States over the past two decades.
- Trial name
- DISC (NCT06085222)
- Testing
- Emotional Engagement Distress Tolerance Intervention, Health Education Intervention
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Florida State University
Cannabis Use Disorder, Cue-reactivity
Semaglutide for the Treatment of Cannabis Use Disorder
The goal of this pilot study is to learn about the effects of semaglutide on brain reactivity to cannabis-related cues in adults with cannabis use disorder. The main questions it aims to answer are: 1.
- Trial name
- S-CUD (NCT07879612)
- Testing
- semaglutide
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Opioid Use Disorder, Cannabis Use
Cannabis Effects on Opioid Self-Administration
The study will enroll participants with opioid use disorder and participants will reside at the University of Kentucky Hospital for this 6-week inpatient trial.
- Trial name
- NCT07668635
- Testing
- Cannabis, Intranasal Opioid Agonist, Oral Opioid Agonist
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Shanna Babalonis, PhD
Schizophrenia and Other Psychotic Disorders, Cannabis Use Disorder
SV2 PET Imaging With [11C]APP311
The aim of this study is to evaluate a new SV2A tracer, [11C]APP311, in healthy aging and neuropsychiatric disorders including psychotic disorders and cannabis use disorders.
- Conditions
- Schizophrenia and Other Psychotic Disorders, Cannabis Use Disorder, Healthy
- Trial name
- SV2 (NCT03995121)
- Testing
- [11C]APP311
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Yale University
Cannabis Use Disorder
Tirzepatide for the Treatment of Cannabis Use Disorder
This is a pilot randomized cross-over trial to examine the effects of tirzepatide on cue-reactivity among individuals with cannabis use disorder.
- Trial name
- NCT07265752
- Testing
- Tirzepatide
- Volunteers
- 6 people
- Sponsor
- Brigham and Women's Hospital
Opioid Use Disorders, Cannabis Use
Cannabis and Opioid Use Disorder, Study 2
This inpatient study enrolls healthy individuals who have opioid use disorder. Participants live at the University of Kentucky Hospital for approx. 6 weeks.
- Trial name
- NCT07661446
- Testing
- Inhaled Cannabis, Intranasal Opioid
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Kentucky
Substance Use, Substance-Related Disorders
Clinician Practice Companion to Address Youth Substance Use
Substance use, including the use of opioids, cannabis, and other drugs, is common among adolescents and young adults, and overdose has become a leading cause of death among youth in Canada and the United States.
- Conditions
- Substance Use, Substance-Related Disorders, Adolescent Substance Use, Cannabis Use
- Trial name
- NCT07725289
- Testing
- Practice Companion
- Where
- 5 sites in United States, Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Alcohol Drinking, Cannabis Use
Cannabis' Impact on Alcohol Consumption
This study employs a repeated measures experimental design to examine the effect of THC-dominant dose of cannabis and CBD-dominant dose of cannabis, relative to placebo, on subsequent drinking in an alcohol choice task in which…
- Conditions
- Alcohol Drinking, Cannabis Use, Cannabis, Alcohol Use Disorder
- Trial name
- NCT05389930
- Testing
- THC-dominant cannabis, CBD-dominant cannabis, Alcohol
- Where
- United States
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Brown University
Cannabis Use Disorder
Endocannabinoids in Reward
This study will examine sex differences in the effects of cannabis in people that regularly use it. Men and women that use cannabis at least 4 days a week will participate in a study involving 3 in-person visits.
- Trial name
- NCT07815691
- Testing
- Dronabinol
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Medical University of South Carolina
ADHD, Cannabis Use Disorder
Delayed-Release, Extended-Release Methylphenidate (Jornay PM) for Adolescents and Young Adults With Attention-Deficit/Hyperactivity Disorder and Cannabis Use Disorder
The goal of this clinical trial is to look at how delayed-release, extended-release methylphenidate (Jornay PM), an FDA-approved medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD), works to treat ADHD…
- Trial name
- NCT07838311
- Testing
- Delayed-release, extended-release methylphenidate
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Massachusetts General Hospital
Cannabis Use Disorder
Lemborexant for Cannabis Use Disorder
The goal of this clinical trial is to investigate the use of Lemborexant as a treatment for moderate to severe Cannabis Use Disorder (CUD). The main questions it aims to answer are: 1.
- Trial name
- LemboCAN (NCT07802990)
- Testing
- Lemborexant 10mg, Brief Behavioural Intervention
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- University of Calgary
Cannabis Use Disorder
Trial of Tirzepatide for the Treatment of Cannabis Use Disorder
The purpose of this randomized, double-blind, placebo-controlled, multi-site clinical trial is to evaluate the safety and efficacy of tirzepatide in a sample of 100 patients diagnosed with moderate or severe CUD by DSM-5 criteria.
- Trial name
- NCT07468552
- Testing
- Tirzepatide
- Volunteers
- 100 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
Psychotic Disorders, Cannabis Use Disorder
Investigating the Neural Correlates of Cognitive Function in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use
Cognitive impairment is well established in people with psychosis and is associated with cannabis use. The current study will investigate the neurobiological basis of cognitive change associated with 28-days of cannabis…
- Conditions
- Psychotic Disorders, Cannabis Use Disorder, Cannabis Dependence, Cannabis Use
- Trial name
- NCT05445180
- Testing
- Contingency management
- Where
- Canada
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Douglas Mental Health University Institute
Cannabis Use Disorder, Mental Health Disorder
Regulated Cannabis Access in Basel
The randomised controlled study on regulated cannabis access in pharmacies in Basel aims to investigate the effects of regulated cannabis access on consumption behaviour and mental and physical health in comparison to the illegal…
- Conditions
- Cannabis Use Disorder, Mental Health Disorder, Physical Illness
- Trial name
- NCT05522205
- Testing
- Regulated cannabis access in pharmacies
- Where
- Switzerland
- Volunteers
- 374 people, healthy volunteers welcome
- Sponsor
- Health Department of the Canton of Basel-Stadt
Schizophrenia, Cannabis Use Disorder
Genetic Basis of the Risk and Consequences of Cannabis Exposure in Humans
Cannabis is widely used worldwide and is associated with negative outcomes including cannabis use disorder (CanUD), psychosis, and cognitive impairment amongst others.
- Trial name
- NCT06058702
- Testing
- Delta-9-THC Very Low Dose, Delta-9-THC Medium Dose
- Where
- United States
- Volunteers
- 215 people, healthy volunteers welcome
- Sponsor
- Yale University
Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe
Psilocybin in the Treatment of Cannabis Use Disorder: A-Proof-of-Concept Study
Cannabis is the most commonly used psychoactive substance in Canada (Lowry \& Corsi, 2020). A sub-group of cannabis users develop a condition known as Cannabis Use Disorder (CUD), which is defined as a regular pattern of cannabis…
- Trial name
- PSI_CUD (NCT06225232)
- Testing
- Psilocybin combined with Psychotherapy
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- McMaster University
Cannabis Use Disorder
Applying Neuromodulation to Boost the Efficacy of Motivational Interviewing
The goal of this clinical trial is to learn how adding brain stimulation to a brief counseling session affects adults with cannabis use disorder.
- Trial name
- NCT07787572
- Testing
- transcranial alternating current stimulation, Motivational interviewing (MI)
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- The Mind Research Network